Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 1025 results for "us fda"

FDA Gives Thumbs Up to Ovarian Cancer Drug Lynparza (Olaparib)
Tech Times

Update: In A Surprise Twist, AstraZeneca Wins Accelerated FDA ...

Summary On Friday, AstraZeneca announced accelerated FDA Approval for Lynparza. This comes a day after the EU approved Lynparza (olaparib). I reiterate my bull thesis on AstraZeneca. The company projects Lynparza to be a $2 billion-a-year seller, ... Seeking Alpha, 3 hours ago
[x]  

350 images for us fda

PRLog, 4 days ago
Proactive Investors.co.uk, 2 days ago
Pharma Letter, 5 days ago
Food Quality, 1 week ago
The Malaysian Times, 1 week ago
Food Quality, 1 week ago
Asiaone, 1 week ago
The Spirits Business, 3 days ago
PRWeb, 2 weeks ago
I4U, 4 days ago

FDA approves Teva allergy spray for children

The QNASL nasal spray, approved for adults in 2012, treats nasal symptoms for allergic rhinitis, including hay fever, in children aged 4-11. Teva Pharmaceutical Industries Ltd. (NYSE: TEVA ; TASE: TEVA ) has announced ...
 Globes15 hours ago Teva Announces FDA Approval of QNASLĀ® (Beclomethasone Dipropionate) Nasal Aerosol for Treatment of Children with Seasonal and Perennial Allergic Rhinitis  Investor's Business Daily2 days ago

INCYTE : Gets FDA Approval for Jakafi (ruxolitinib)

Incyte Corp. recently reported that the U.S. Food and Drug Administration (FDA) has approved Jakafi (ruxolitinib) for the treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. ...
 4 Traders18 hours ago FDA approves Viekira Pak to treat hepatitis C  FierceBiotech2 days ago FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection  News-Medical.Net7 hours ago 12/21/14 - Incyte Gets FDA Approval for Jakafi (ruxolitinib) [Professional Services Close - Up]  Pharmacy Choice11 hours ago
[x]  
Bidness Etc

FDA Gives Green Signal To AbbVie's (ABBV) Hepatitis C Treatment

The US Food and Drug Administration (FDA) approved AbbVie Inc's ( NYSE:ABBV ) new combo regimen for hepatitis C on Friday, paving the way for the company to go head to head with Gilead Sciences, Inc. ( NASDAQ:GILD ) in the hepatitis C space. ...
 Bidness Etc1 day ago FDA approves AbbVie combo hepatitis C treatment  Crains ChicagoBusiness2 days ago FDA Approves AbbVie's Hepatitis Treatment  Austin American Statesman2 days ago FDA approves new hepatitis C treatment  Boston Globe2 days ago
[x]  
Bidness Etc

FDA Okays Cubist Pharmaceuticals (CBST) Drug For Antibiotic-Resistant Bacteria

The US Food and Drug Administration (FDA) on Friday approved Cubist Pharmaceuticals, Inc.'s ( NASDAQ:CBST ) experimental antibiotic Zerbaxa for the treatment of complicated urinary tract infection (cUTI) and complicated intra-abdominal infection ...
 Bidness Etc1 day ago FDA Approves Cubist's Experimental Antibiotic Zerbaxa  Austin American Statesman2 days ago Cubist Gets FDA Approval Of New Antibiotic Zerbaxa  RTTNews.com2 days ago FDA approves new antibacterial drug Zerbaxa  U.S. Food and Drug Administration1 day ago
[x]  

Cerus Soaring On FDA Approval Of Intercept

Summary Cerus has received approval for its INTERCEPT blood system from the FDA. Last month, the company received approval to treat Ebola survivor plasma for passive immune therapy. With the platelet treatment approval on the horizon, 2015 can be ...
 Seeking Alpha1 day ago FDA Approves INTERCEPT Blood System for Platelets  Investor's Business Daily2 days ago Leukemia drug gets FDA approval due, in part, to City of Hope researcher  City of Hope2 days ago Small cap Cerus spikes on back-to-back Intercept approvals by FDA  FierceMedicalDevices2 days ago
[x]  

FDA Ruling Blocking Celebrex Generics Voided in Mylan Win

A U.S. appeals court reversed a Food and Drug Administration ruling that effectively blocked until June Mylan Pharmaceuticals Inc., Watson Laboratories Inc. and Lupin Pharmaceuticals Inc. from selling generic versions of the arthritis drug Celebrex, ...
 Bloomberg1 day ago Court reverses FDA ruling blocking generic Celebrexvisit|article-5961436|river-44317-1col-hp-38|1  San Francisco Chronicle2 days ago
Bidness Etc

Herbalife Ltd. (HLF): Letter From FDA Is Not A Big Problem

By: Published: Dec 20, 2014 at 9:09 am EST Herbalife Ltd. ( NYSE:HLF ) shares fell about 2.2% from $38.8 near 15:00 ET to $37.96 by the time market closed yesterday. This might be because of a letter that Michael R. Taylor, ...
 Bidness Etc1 day ago

HEPATIQ(TM) Receives FDA Clearance

IRVINE, Calif.--(BUSINESS WIRE)-- HEPATIQ LLC announced that they received clearance from the United States Food & Drug Administration to market their HEPATIQ software. HEPATIQ is a nuclear medicine software application used to display and process ...
 CNBC2 days ago HEPATIQ Receives FDA Clearance  Minyanville2 days ago DiaSorin receives FDA clearance for vitamin D determination test in US  Individual.com3 days ago HEPATIQ? Receives FDA Clearance  Pharmacy Choice1 day ago
[x]  

FDA approves Cubists' drug for antibiotic-resistant bacteria

Dec 19 (Reuters) - Cubist Pharmaceutical Inc's drug to treat complicated urinary tract and intra-abdominal infections won U.S. approval on Friday, highlighting the regulator's interest in tackling the growing threat of the so-called superbugs. ...
 CNBC2 days ago Superbug-fighting Cubist antibiotic wins FDA nod  Boston Globe2 days ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less